We are partner organization in the EUROoC!
We are partner organization in the European interdisciplinary training network for organ-on-chip technology (EUROoC)
What does it mean to work with organ-on-chip? What is 3R? Where are the opportunities and benefits for understanding human cellular mechanisms, modeling human diseases, and screening drugs?
The field of organ-on-chip (OoC) rapidly moved forward due to its promising impact on drug development and personalized disease treatment. Because of this, EUROoC, the first European training program on OoC, was founded. Participants from different disciplines, such as biology, engineering, medicine, physics and chemistry come together. The common aim: the reduction of animal experiments. The University Hospital Jena is represented by the doctoral student Aina Kehinde Oluwasegun and our biotech chips.
EUROoC invites you to a virtual lab tour in the clip “Organ-on-Chip and the 3R: A virtual lab tour”. Here you will get insights into the Europe-wide OoC research.
Our biochips are presented in minutes three and five.
More news from Dynamic42:
Blog, Disease-Modeling, Gut-on-Chip, Infection-Modeling
When butyrate drops, the gut loses more than a metabolite – it loses resilience
In this new study by Manuel Allwang, Maximilian Wipplinger, and Parastoo Akbarimoghaddam and colleagues, published in Small, the authors show why that loss may be especially important when inflamed tissue is challenged by the opportunistic fungus Candida albicans.
Read MoreBlog, Drug Development, Liver-on-Chip
Evaluation of a liver-chip model for clearance prediction
In this new publication led by scientists at Novartis and the University of Tübingen, the authors take a deep, engineering level look at the performance of a microphysiological liver on chip model for predicting human hepatic clearance, a central parameter in preclinical drug development.
Read MoreBlog, Gut-on-Chip, Infection-Modeling
Modeling Clostridioides difficile toxin pathogenesis and antiserum protection
In this new study from Jena University Hospital and the Paul-Ehrlich-Institute, the authors show that how we model Clostridioides difficile toxin exposure fundamentally shapes our ability to understand epithelial damage, immune activation, and therapeutic protection.
Read More